{"id":"mitomycin-doxifluridine-and-cisplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nephrotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mitomycin is an alkylating agent that cross-links DNA strands; doxifluridine is a fluoropyrimidine that inhibits thymidylate synthase and gets incorporated into DNA/RNA; cisplatin is a platinum compound that forms DNA adducts. Together, they provide synergistic cytotoxic effects against cancer cells through multiple mechanisms of DNA damage and replication inhibition.","oneSentence":"This combination of three chemotherapy agents works by damaging DNA and inhibiting nucleotide synthesis to kill rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:04.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer (Phase 3 trial indication)"}]},"trialDetails":[{"nctId":"NCT00296322","phase":"PHASE3","title":"Trial of Adjuvant Chemotherapy for Gastric Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2001-10","conditions":"Stomach Cancer","enrollment":528},{"nctId":"NCT00296335","phase":"PHASE3","title":"Trial of Adjuvant Chemotherapy for Gastric Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2002-02","conditions":"Stomach Cancer","enrollment":855}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mitomycin, doxifluridine and cisplatin","genericName":"Mitomycin, doxifluridine and cisplatin","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of three chemotherapy agents works by damaging DNA and inhibiting nucleotide synthesis to kill rapidly dividing cancer cells. Used for Gastric cancer (Phase 3 trial indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}